ITUB20153238A1 - Induction of Emx2 expression and its use in the treatment of gliomas - Google Patents

Induction of Emx2 expression and its use in the treatment of gliomas

Info

Publication number
ITUB20153238A1
ITUB20153238A1 ITUB2015A003238A ITUB20153238A ITUB20153238A1 IT UB20153238 A1 ITUB20153238 A1 IT UB20153238A1 IT UB2015A003238 A ITUB2015A003238 A IT UB2015A003238A IT UB20153238 A ITUB20153238 A IT UB20153238A IT UB20153238 A1 ITUB20153238 A1 IT UB20153238A1
Authority
IT
Italy
Prior art keywords
emx2
gliomas
induction
expression
treatment
Prior art date
Application number
ITUB2015A003238A
Other languages
Italian (it)
Inventor
Antonio Mallamaci
Carmen Falcone
Original Assignee
S I S S A Scuola Int Superiore Di Studi Avanzati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S I S S A Scuola Int Superiore Di Studi Avanzati filed Critical S I S S A Scuola Int Superiore Di Studi Avanzati
Priority to ITUB2015A003238A priority Critical patent/ITUB20153238A1/en
Priority to PCT/EP2016/070164 priority patent/WO2017032869A1/en
Publication of ITUB20153238A1 publication Critical patent/ITUB20153238A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITUB2015A003238A 2015-08-26 2015-08-26 Induction of Emx2 expression and its use in the treatment of gliomas ITUB20153238A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITUB2015A003238A ITUB20153238A1 (en) 2015-08-26 2015-08-26 Induction of Emx2 expression and its use in the treatment of gliomas
PCT/EP2016/070164 WO2017032869A1 (en) 2015-08-26 2016-08-26 Induction of the expression of emx2 and use thereof in the treatment of gliomas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2015A003238A ITUB20153238A1 (en) 2015-08-26 2015-08-26 Induction of Emx2 expression and its use in the treatment of gliomas

Publications (1)

Publication Number Publication Date
ITUB20153238A1 true ITUB20153238A1 (en) 2017-02-26

Family

ID=55069946

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2015A003238A ITUB20153238A1 (en) 2015-08-26 2015-08-26 Induction of Emx2 expression and its use in the treatment of gliomas

Country Status (2)

Country Link
IT (1) ITUB20153238A1 (en)
WO (1) WO2017032869A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11827884B2 (en) 2017-05-15 2023-11-28 University Of Florida Research Foundation, Incorporated Core master regulators of glioblastoma stem cells
CN110241210B (en) * 2019-06-11 2023-02-10 复旦大学 RIT1Application of gene as intervention target of drug for treating brain glioma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832604A1 (en) * 2006-03-10 2007-09-12 TIMA Foundation Use of IEX-1 for the treatment of glioma tumors
CN101760474A (en) * 2008-12-25 2010-06-30 许军普 EMX2 adenovirus vector and application thereof
US20100233703A1 (en) * 2009-02-06 2010-09-16 The Regents Of The University Of California Emx2 in cancer diagnosis and prognosis
WO2011045765A1 (en) * 2009-10-14 2011-04-21 Scuola Internazionale Superiore Di Studi Avanzati TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832604A1 (en) * 2006-03-10 2007-09-12 TIMA Foundation Use of IEX-1 for the treatment of glioma tumors
CN101760474A (en) * 2008-12-25 2010-06-30 许军普 EMX2 adenovirus vector and application thereof
US20100233703A1 (en) * 2009-02-06 2010-09-16 The Regents Of The University Of California Emx2 in cancer diagnosis and prognosis
WO2011045765A1 (en) * 2009-10-14 2011-04-21 Scuola Internazionale Superiore Di Studi Avanzati TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE LI ET AL: "Adenoviral Delivery of the EMX2 Gene Suppresses Growth in Human Gastric Cancer", PLOS ONE, vol. 7, no. 9, 21 September 2012 (2012-09-21), pages e45970, XP055265275, DOI: 10.1371/journal.pone.0045970 *

Also Published As

Publication number Publication date
WO2017032869A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
LTC3057969I2 (en) COMPOSITIONS USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH KIT
DK3283106T3 (en) Therapeutic antibodies and uses thereof
KR20180084817A (en) Anti-SIGLEC-9 antibodies and methods of using the same
DK3267960T3 (en) STIMULATION DEVICE WITH EXTENSION
DK3142637T3 (en) KERATIN TREATMENT FORMULATIONS AND METHODS
BR112016016289A2 (en) heteroari and uses thereof
DK3018183T3 (en) HALOGENOLEFIN BASED COMPOSITION AND USE THEREOF
MA41794A (en) MODIFIED THERAPEUTIC AGENTS AND ASSOCIATED COMPOSITIONS
DK3231444T3 (en) New treatment
DK3253800T3 (en) Prostate antigen standards and use thereof
DK3374497T3 (en) MODIFIED MACROPHAGE FOR USE IN THE TREATMENT OF CANCER
DK3393478T3 (en) combination therapy
DK3110447T3 (en) Anti-EGFR antibody and its applications
DK3606926T3 (en) HETEROAROMATIC COMPOUNDS USE IN THERAPY
DK3532059T3 (en) COMBINATION THERAPY WITH BROMDOMAIN AND EXTRA TERMINAL PROTEIN INHIBITOR
DK3408265T3 (en) THERAPEUTIC RELATIONS
KR20180084747A (en) GALGT2 gene therapy methods and materials
DK3383872T3 (en) 1,3,4-THIADIAZOLIC COMPOUNDS AND ITS USE IN CANCER TREATMENT
DK3164123T3 (en) Novel uses of benzylideneguanidine derivatives in the treatment of proteopathies
DK3321279T3 (en) EXENATID MODIFICANT AND USE THEREOF
DK3365321T3 (en) SOLABEGRON-ZWITTERION AND USES THEREOF
DK3302478T3 (en) PAC-1 COMBINATION TREATMENT
BR112017018932A2 (en) etv2 and uses thereof
DK3383871T3 (en) 1,3,4-THIADIAZOLIC COMPOUNDS AND ITS USE IN CANCER TREATMENT
DK3380468T3 (en) BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT